At the 42nd Annual Meeting of the Japanese Society of Toxicologic Pathology (https://cfmeeting.com/jstp42/en/ ), Dr. Yamamoto from our company delivered a presentation at the symposium titled “NAMs and Toxicologic Pathology.” His talk was entitled “Drug Discovery Applications of Lung Organoids and Future Perspectives.”
Pulmonary toxicity remains one of the most critical challenges in anticancer drug development. To address this issue, we have established a lung toxicity evaluation platform based on human lung organoids, part of which is offered as a CRO service. These initiatives are gaining increasing attention both in Japan and internationally, and novel insights are steadily being accumulated.
In addition to anticancer drugs, this platform is also being applied to the assessment of pulmonary toxicity induced by environmental toxicants. If you are interested in our technology or services, please feel free to contact us.